Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Telescope InnovationsTELIF -4.41%33 Equity-to-Asset is 0.50 as of May. 2026, which is at its 10-year median of 0.50. GuruFocus rates TELIF with a GF Score™ of 33/100 and a GF Value™ of $0.39 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,414 Biotechnology companies, Telescope Innovations ranks worse than 66.55% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Telescope Innovations Equity-to-Asset Related Terms
Telescope Innovations Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Telescope Innovations's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELIF vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Telescope Innovations's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telescope Innovations Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telescope Innovations's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Telescope Innovations's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Telescope Innovations's Equity to Asset Ratio for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Telescope Innovations (TELIF) has a Equity-to-Asset of 0.50 as of May. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Telescope Innovations and its competitors. This is near median its historical median of 0.50. According to the industry distribution chart, Telescope Innovations ranks #941 out of 1414 companies in the Biotechnology industry, placing it in the top 66.5%.
Is Telescope Innovations' Equity-to-Asset too high?
Telescope Innovations' current Equity-to-Asset of 0.50 is near median its 10-year median of 0.50. The Biotechnology industry median Equity-to-Asset is 0.68. Telescope Innovations' value of 0.50 is 26.5% below this industry median. Based on the distribution chart, Telescope Innovations ranks #941 out of 1414 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Telescope Innovations has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Telescope Innovations' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telescope Innovations ranks #941 out of 1414 companies for Equity-to-Asset. This places Telescope Innovations in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Telescope Innovations' value of 0.50 is 26.5% below this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 0.68, Telescope Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Telescope Innovations's current Equity-to-Asset of 0.50 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Telescope Innovations and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Telescope Innovations's current Equity-to-Asset is 0.50, which is near median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telescope Innovations stock overvalued right now?
Based on GuruFocus' analysis, Telescope Innovations (TELIF) is currently considered Fairly Valued. The stock's GF Value™ is $0.39, compared to a current price of $0.36 — trading 6.9% below its estimated fair value. The current Equity-to-Asset is 0.50, which is near median its 10-year median of 0.50 and 26.5% below the Biotechnology industry median of 0.68. Telescope Innovations' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Telescope Innovations (TELIF), the current Equity-to-Asset is 0.50 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telescope Innovations (TELIF) Overvalued in 2026?
Based on GuruFocus' analysis, Telescope Innovations stock appears to be undervalued.
The current stock price of $0.36 is trading 6.9% below its estimated GF Value™ of $0.39.
GuruFocus considers Telescope Innovations to be Fairly Valued.
Key valuation signals for TELIF:
Equity-to-Asset: 0.50 (near median its 10-year median of 0.50)
GF Value™: $0.39 vs. price of $0.36 (6.9% below fair value)
Industry Position: 26.5% below the Biotechnology median (#941 of 1414)
No single metric tells the full story. See the TELIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telescope Innovations Corp is a technology company focused on development as a Contract Research Organization (CRO) to develop intellectual property, provide contract research, and build automation products, and operates as a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. Its flagship product is the DirectInject-LC system. The Company operates in a single operating segment and generates revenue from three streams: contract research services, grant income, and the sale of automation products, with the majority of revenue derived from automation product sales from customer contracts. It operates in Canada, the United States, Europe, and Asia, with the majority of revenue coming from the United States.
33GF Score
Get the complete analysis for TELIF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELIF has been successfully added to your 
